NZ612173B2 - Process and intermediates for synthesizing agomelatine - Google Patents
Process and intermediates for synthesizing agomelatine Download PDFInfo
- Publication number
- NZ612173B2 NZ612173B2 NZ612173A NZ61217312A NZ612173B2 NZ 612173 B2 NZ612173 B2 NZ 612173B2 NZ 612173 A NZ612173 A NZ 612173A NZ 61217312 A NZ61217312 A NZ 61217312A NZ 612173 B2 NZ612173 B2 NZ 612173B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- formula
- synthesis
- yield
- subjected
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 29
- 230000002194 synthesizing Effects 0.000 title claims abstract description 29
- YJYPHIXNFHFHND-UHFFFAOYSA-N Agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 title claims abstract description 18
- 229960002629 agomelatine Drugs 0.000 title claims abstract description 15
- 239000000543 intermediate Substances 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 28
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 28
- SJNALLRHIVGIBI-UHFFFAOYSA-N Allyl cyanide Chemical compound C=CCC#N SJNALLRHIVGIBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 16
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 claims description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 14
- MVPPADPHJFYWMZ-UHFFFAOYSA-N Chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000007868 Raney catalyst Substances 0.000 claims description 7
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 238000007792 addition Methods 0.000 claims description 6
- 238000005899 aromatization reaction Methods 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- UGNWTBMOAKPKBL-UHFFFAOYSA-N Chloranil Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 claims description 5
- 239000003999 initiator Substances 0.000 claims description 5
- SMZOGRDCAXLAAR-UHFFFAOYSA-N Aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 claims description 4
- 238000007348 radical reaction Methods 0.000 claims description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-Benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 2
- 230000003197 catalytic Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 description 7
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RGKQBIJMCKYIGP-UHFFFAOYSA-N 2-(7-methoxy-1,2-dihydronaphthalen-1-yl)acetonitrile Chemical compound C1=CCC(CC#N)C2=CC(OC)=CC=C21 RGKQBIJMCKYIGP-UHFFFAOYSA-N 0.000 description 3
- PYJMGUQHJINLLD-UHFFFAOYSA-N 2-(7-methoxynaphthalen-1-yl)acetonitrile Chemical compound C1=CC=C(CC#N)C2=CC(OC)=CC=C21 PYJMGUQHJINLLD-UHFFFAOYSA-N 0.000 description 3
- GABLTKRIYDNDIN-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2H-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(OC)=CC=C21 GABLTKRIYDNDIN-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- -1 xanthate compound Chemical class 0.000 description 2
- WJBBNWUFOLRXAL-UHFFFAOYSA-N (4-propan-2-ylphenyl) 2,2,5,5-tetramethylhexaneperoxoate Chemical compound CC(C)C1=CC=C(OOC(=O)C(C)(C)CCC(C)(C)C)C=C1 WJBBNWUFOLRXAL-UHFFFAOYSA-N 0.000 description 1
- NOBYOEQUFMGXBP-UHFFFAOYSA-N (4-tert-butylcyclohexyl) (4-tert-butylcyclohexyl)oxycarbonyloxy carbonate Chemical compound C1CC(C(C)(C)C)CCC1OC(=O)OOC(=O)OC1CCC(C(C)(C)C)CC1 NOBYOEQUFMGXBP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-Tetralone Chemical compound C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 description 1
- XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 description 1
- JFBNNQVFHPDQAE-UHFFFAOYSA-N 2-(7-methoxy-2-oxo-3,4-dihydro-1H-naphthalen-1-yl)acetonitrile Chemical compound C1CC(=O)C(CC#N)C2=CC(OC)=CC=C21 JFBNNQVFHPDQAE-UHFFFAOYSA-N 0.000 description 1
- ZACVGCNKGYYQHA-UHFFFAOYSA-N 2-ethylhexoxycarbonyloxy 2-ethylhexyl carbonate Chemical compound CCCCC(CC)COC(=O)OOC(=O)OCC(CC)CCCC ZACVGCNKGYYQHA-UHFFFAOYSA-N 0.000 description 1
- JJRDRFZYKKFYMO-UHFFFAOYSA-N 2-methyl-2-(2-methylbutan-2-ylperoxy)butane Chemical compound CCC(C)(C)OOC(C)(C)CC JJRDRFZYKKFYMO-UHFFFAOYSA-N 0.000 description 1
- AQKYLAIZOGOPAW-UHFFFAOYSA-N 2-methylbutan-2-yl 2,2-dimethylpropaneperoxoate Chemical compound CCC(C)(C)OOC(=O)C(C)(C)C AQKYLAIZOGOPAW-UHFFFAOYSA-N 0.000 description 1
- ZIDNXYVJSYJXPE-UHFFFAOYSA-N 2-methylbutan-2-yl 7,7-dimethyloctaneperoxoate Chemical compound CCC(C)(C)OOC(=O)CCCCCC(C)(C)C ZIDNXYVJSYJXPE-UHFFFAOYSA-N 0.000 description 1
- RPBWMJBZQXCSFW-UHFFFAOYSA-N 2-methylpropanoyl 2-methylpropaneperoxoate Chemical compound CC(C)C(=O)OOC(=O)C(C)C RPBWMJBZQXCSFW-UHFFFAOYSA-N 0.000 description 1
- BIISIZOQPWZPPS-UHFFFAOYSA-N 2-tert-butylperoxypropan-2-ylbenzene Chemical compound CC(C)(C)OOC(C)(C)C1=CC=CC=C1 BIISIZOQPWZPPS-UHFFFAOYSA-N 0.000 description 1
- 206010060961 Appetite disease Diseases 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 206010009191 Circadian rhythm sleep disease Diseases 0.000 description 1
- 229940057404 DI-(4-TERT-BUTYLCYCLOHEXYL)PEROXYDICARBONATE Drugs 0.000 description 1
- LSXWFXONGKSEMY-UHFFFAOYSA-N Di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N Ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 108040006927 G protein-coupled serotonin receptor activity proteins Proteins 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010057840 Major depression Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N Octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 206010039775 Seasonal affective disease Diseases 0.000 description 1
- 206010040984 Sleep disease Diseases 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N Trifluorotoluene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- ZGPBOPXFOJBLIV-UHFFFAOYSA-N butoxycarbonyloxy butyl carbonate Chemical compound CCCCOC(=O)OOC(=O)OCCCC ZGPBOPXFOJBLIV-UHFFFAOYSA-N 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- XJOBOFWTZOKMOH-UHFFFAOYSA-N decanoyl decaneperoxoate Chemical compound CCCCCCCCCC(=O)OOC(=O)CCCCCCCCC XJOBOFWTZOKMOH-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- QWVBGCWRHHXMRM-UHFFFAOYSA-N hexadecoxycarbonyloxy hexadecyl carbonate Chemical compound CCCCCCCCCCCCCCCCOC(=O)OOC(=O)OCCCCCCCCCCCCCCCC QWVBGCWRHHXMRM-UHFFFAOYSA-N 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001193 melatoninergic Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- HJCRVWSKQNDSPZ-UHFFFAOYSA-N propan-2-olate;samarium(3+) Chemical compound [Sm+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] HJCRVWSKQNDSPZ-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- PFBLRDXPNUJYJM-UHFFFAOYSA-N tert-butyl 2-methylpropaneperoxoate Chemical compound CC(C)C(=O)OOC(C)(C)C PFBLRDXPNUJYJM-UHFFFAOYSA-N 0.000 description 1
- UXPDDYBTPCKLAV-UHFFFAOYSA-N tert-butyl 3-(2,2-dimethylpropyl)dioxirane-3-carboxylate Chemical compound CC(C)(C)OC(=O)C1(CC(C)(C)C)OO1 UXPDDYBTPCKLAV-UHFFFAOYSA-N 0.000 description 1
- NMOALOSNPWTWRH-UHFFFAOYSA-N tert-butyl 7,7-dimethyloctaneperoxoate Chemical compound CC(C)(C)CCCCCC(=O)OOC(C)(C)C NMOALOSNPWTWRH-UHFFFAOYSA-N 0.000 description 1
- GJBRNHKUVLOCEB-UHFFFAOYSA-N tert-butyl benzenecarboperoxoate Chemical compound CC(C)(C)OOC(=O)C1=CC=CC=C1 GJBRNHKUVLOCEB-UHFFFAOYSA-N 0.000 description 1
- SWAXTRYEYUTSAP-UHFFFAOYSA-N tert-butyl ethaneperoxoate Chemical compound CC(=O)OOC(C)(C)C SWAXTRYEYUTSAP-UHFFFAOYSA-N 0.000 description 1
- CSKKAINPUYTTRW-UHFFFAOYSA-N tetradecoxycarbonyloxy tetradecyl carbonate Chemical compound CCCCCCCCCCCCCCOC(=O)OOC(=O)OCCCCCCCCCCCCCC CSKKAINPUYTTRW-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/06—Preparation of carboxylic acid amides from nitriles by transformation of cyano groups into carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/40—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
612173 Disclosed is a process for the industrial synthesis of agomelatine (formula I) from the allyl cyanide of formula (II) and a compound of formula (III), wherein Xa is an -S-C(S)-OR group in which R is a linear or branched (C-C) alkyl group. Also disclosed are intermediates in the synthesis. (...)
Description
P PR RO OC CE ES SS S A AN ND D I IN NT TE ER RM ME ED DI IA AT TE ES S F FO OR R S SY YN NT TH HE ES SI IZ ZI IN NG G A AG GO OM ME EL LA AT TI IN NE E
The present invention relates to a new process for the industrial synthesis of agomelatine,
or N-[2-(7-methoxynaphthyl)ethyl]acetamide, of formula (I):
NHCOMe
(I).
Agomelatine, or N-[2-(7-methoxynaphthyl)ethyl]acetamide, has valuable
pharmacological properties.
It has, in fact, the double characteristic of being, on the one hand, an agonist of receptors of
the melatoninergic system and, on the other hand, an antagonist of the 5-HT receptor.
These properties provide it with activity in the central nervous system and, more
especially, in the treatment of major depression, seasonal affective disorder, sleep
disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and
fatigue due to jet-lag, appetite disorders and obesity.
Agomelatine, its preparation and its use in therapeutics have been described in European
patent specifications EP 0 447 285 and EP 1 564 202.
In view of the pharmaceutical value of this compound, it has been important to be able to
produce it using an effective industrial synthesis process which is readily transferable to
the industrial scale and which provides agomelatine in a good yield and with excellent
purity.
Patent specification EP 0 447 285 describes production of agomelatine in eight steps
starting from 7-methoxytetralone.
In patent specification EP 1 564 202, the Applicant developed a new, much more effective
and industrialisable synthesis route in only four steps starting from 7-methoxytetralone
that makes it possible to obtain agomelatine in highly reproducible manner in a well-
defined crystalline form.
However, the search for new synthesis routes, especially starting from starting materials
that are less costly than 7-methoxytetralone, is currently still relevant.
The Applicant has continued his investigations and has developed a new process for the
synthesis of agomelatine starting from allyl cyanide and a xanthate compound: these new
starting materials have the advantage of being simple and readily obtainable in large
quantities at less cost.
This synthesis route is based on carrying out free radical reactions that are not very
commonly used but are nevertheless very effective. Converting these reactions to the
industrial scale using continuous-flow reactors is promising as it becomes simpler to
control propagation of the chain reaction.
This new process moreover makes it possible to obtain agomelatine in reproducible
manner and without requiring laborious purification, with a purity that is compatible with
its use as a pharmaceutical active ingredient. Indeed, agomelatine can accordingly be
synthesised in 6 steps in the course of which only two of the intermediates are isolated.
More specifically, the present invention relates to a process for the industrial synthesis of
the compound of formula (I):
NHCOMe
(I),
which process is characterised in that allyl cyanide of formula (II):
(II)
is reacted, in the presence of a free radical initiator, with a compound of formula (III):
(III),
wherein Xa represents a group -S-C(S)-OR in which R represents a linear or branched
(C -C )alkyl group,
to yield the compound of formula (IV):
(IV),
wherein Xa is as defined hereinbefore,
it being possible for this latter compound optionally to be isolated, before being subjected
to a cyclisation reaction in the presence of a free radical initiator in order to form the
compound of formula (V):
(V),
which compound of formula (V) also optionally may be isolated,
which is subjected to a reduction-dehydration reaction to yield the compound of
formula (VI):
(VI),
which is then subjected to an aromatisation reaction to yield the compound of
formula (VII):
(VII),
which is subjected to reduction using hydrogen in the presence of Raney nickel in a polar
protic medium and to reaction with acetic anhydride to yield the compound of formula (I),
which is isolated in the form of a solid.
In a preferred embodiment of the invention, the compound of formula (VII) is then
subjected to reduction using hydrogen in the presence of Raney nickel in an ammoniacal
ethanol medium and then converted into a salt using hydrochloric acid to yield the
compound of formula (VIII):
(VIII),
which is successively subjected to the action of sodium acetate and then acetic anhydride
to yield the compound of formula (I), which is isolated in the form of a solid.
Alternatively, the compound of formula (VII) can be subjected to reduction by hydrogen in
the presence of Raney nickel in a medium comprising acetic anhydride in a polar protic
medium to yield the compound of formula (I), which is isolated in the form of a solid.
In a preferred compound of formula (III), Xa represents a group -S-C(S)-OC H .
In the processes according to the invention, initiation of the free radical reactions is carried
out by thermal means. Preferably, the reaction mixture is heated to a temperature of from
50°C to 140°C. Even more preferably, cyclisation is carried out at a temperature of from
130 to 135°C.
Peroxides are free radical initiators that are especially suitable for carrying out the step of
addition of the compound of formula (II) to the compound of formula (III), or for
performing cyclisation of the compound of formula (IV) to form the compound of
formula (V). By way of example, there may be mentioned, especially, diisobutyryl
peroxide, cumyl peroxyneodecanoate, tert-amyl peroxyneodecanoate, di(2-ethylhexyl)
peroxydicarbonate, tert-butyl peroxyneodecanoate, dibutyl peroxydicarbonate, dicetyl
peroxydicarbonate, dimyristyl peroxydicarbonate, tert-butyl peroxyneoheptanoate, tert-
amyl peroxypivalate, didecanoyl peroxide, tert-amyl peroxyethylhexanoate, tert-butyl
peroxyisobutyrate, 1,4-di(tert-butylperoxycarbo)cyclohexane, tert-butyl peroxyacetate,
tert-butyl peroxybenzoate, di-tert-amyl peroxide, tert-butyl cumyl peroxide, bis(tert-butyl)
peroxide, dicumyl peroxide, dilauroyl peroxide (DLP) or di(4-tert-butylcyclohexyl)
peroxydicarbonate.
Preferably, the reaction is initiated in the presence of dilauroyl peroxide.
The amount of dilauroyl peroxide used in the cyclisation is preferably from 1 to 2.5
equivalents.
In a preferred embodiment of the invention, dilauroyl peroxide is added to the medium in
stages.
The addition and/or cyclisation reactions are carried out in a solvent customarily used in
free radical chemistry such as 1,2-dichloroethane, dichloromethane, benzene, toluene,
trifluoromethylbenzene, chlorobenzene, hexane, cyclohexane, heptane, octane, ethyl
acetate, tert-butyl alcohol, and mixtures thereof.
Preference is given to using ethyl acetate in the step of addition of the compound of
formula (II) to the compound of formula (III), whilst cyclisation of the compound of
formula (IV) to form the compound of formula (V) is advantageously carried out in
chlorobenzene, ethyl acetate or ethyl butyrate. In this latter reaction, chlorobenzene is more
especially preferred.
Conversion of the compound of formula (V) into the compound of formula (VI) is
advantageously carried out in the presence of a Lewis acid such as aluminium
isopropoxide or samarium isopropoxide. This conversion is moreover preferably carried
out in an alcohol (primary or secondary), and even more preferably in isopropanol.
Preferably, a catalytic amount of p-toluenesulphonic acid is added to the mixture once all
the tetralone (V) has been consumed at the end of conversion of the compound of
formula (V) into the compound of formula (VI).
Aromatisation of compound (VI) is carried out in the presence of a quinone, preferably in
the presence of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or tetrachlorobenzo-
quinone (TCQ). Even more preferably, aromatisation is carried out in the presence of TCQ
at the reflux of toluene.
The compound of formula (II) is accessible to the person skilled in the art by means of
conventional chemical reactions and/or chemical reactions described in the literature.
This process is especially valuable for the following reasons:
- it makes it possible to obtain the compound of formula (I) on an industrial scale in
good yields, starting from a simple, low-cost starting material;
- only the intermediates of formulae (VI) and (VII) require a purification and
isolation step.
The compounds of formulae (V) and (VI) obtained according to the process of the
invention are new and useful as intermediates in the synthesis of agomelatine.
The Examples hereinbelow illustrate the invention without limiting it in any way.
For the purpose of validating the reaction route, the synthesis intermediates were
systematically isolated and characterised. However, it is possible to considerably optimise
the procedures by limiting the number of intermediates isolated. Accordingly, Example 2
given hereinbelow corresponds to the same reaction route as that used in Example 1 but
with the difference that only (7-methoxy-1,2-dihydronaphthyl)acetonitrile and (7-
methoxynaphthyl)acetonitrile were isolated.
In this specification where reference has been made to patent specifications, other external
documents, or other sources of information, this is generally for the purpose of providing a
context for discussing the features of the invention. Unless specifically stated otherwise,
reference to such external documents is not to be construed as an admission that such
documents, or such sources of information, in any jurisdiction, are prior art, or form part of
the common general knowledge in the art.
In the description in this specification reference may be made to subject matter that is not
within the scope of the claims of the current application. That subject matter should be
readily identifiable by a person skilled in the art and may assist in putting into practice the
invention as defined in the claims of this application.
The term 'comprising' as used in this specification and claims means 'consisting at least in
part of'. When interpreting statements in this specification and claims which include the
term 'comprising', other features besides the features prefaced by this term in each
statement can also be present. Related terms such as 'comprise' and 'comprised' are to be
interpreted in similar manner.
E Ex xa am mp plle e 1 1: : N N- -[ [2 2- -( (7 7- -M Me et th ho ox xy y- -1 1- -n na ap ph ht th hy yll) )e et th hy yll] ]a ac ce et ta am miid de e
Step A: S S- -[ [1 1- -( (c cy ya an no om me etth hy yll) )- -4 4- -( (4 4- -m me etth ho ox xy yp ph he en ny yll) )- -4 4- -o ox xo ob bu utty yll] ]- -O O- -e etth hy yll
d diitth hiio oc ca ar rb bo on na atte e
A solution of allyl cyanide (4.8 mL, 60.0 mmol) and S-[2-(4-methoxyphenyl)oxoethyl]-
O-ethyl dithiocarbonate (8.1 g, 30.0 mmol) in ethyl acetate (30 mL) is heated at reflux for
15 minutes under a nitrogen atmosphere. There is added, firstly, an amount of dilauroyl
peroxide (10 mol%) to the solution under reflux. After 1 hour 30 minutes, another amount
of dilauroyl peroxide (5 mol%) is also introduced. When the reagents have been
completely consumed, the mixture is cooled to ambient temperature and concentrated
under reduced pressure. The crude mixture is then purified by flash column
chromatography (petroleum ether-ethyl acetate: 95-5 to 80-20) to yield the title compound
in the form of an oil in a yield of 98%.
7.93 (m, 2H, CH-4), 6.93 (m, 2H, CH-3), 4.67-4.57 (m, 2H, CH -13),
H NMR (δ, ppm)
3.99 (m, 1H, CH-9), 3.87 (s, 3H, CH -1), 3.15 (t, 2H, J = 7.3 Hz,
(CDCl , 400 MHz)
CH -7), 2.95 (dd, 2H, J = 17.0, 6.0 Hz, CH -10), 2.41-2.31 (m, 1H,
CH -8), 2.19-2.08 (m, 1H, CH -8), 1.41 (t, 3H, J = 7.1 Hz, CH -14).
2 2 3
Step B: (7-Methoxyoxo-1,2,3,4-tetrahydronaphthyl)acetonitrile
The compound of Step A, used directly without having been purified, is redissolved in
chlorobenzene (900 mL) and the solution is refluxed for 15 minutes under a nitrogen
atmosphere. Dilauroyl peroxide is then gradually added to the solution under reflux
(10 mol% every 10 minutes). When the reaction is complete, the mixture is cooled to
ambient temperature and concentrated under reduced pressure. Acetonitrile is then
introduced in order to cause a large part of the dilauroyl peroxide compounds to precipitate
out. The mixture is then filtered, concentrated under reduced pressure and purified by flash
column chromatography (petroleum ether-ethyl acetate: 60-40) to yield the title compound
in solid form in a yield of 40%.
HRMS (EI, m/z) Calc. for C H NO : 215.0946; found: 215.0946.
13 13 2
Step C: (7-Methoxy-1,2-dihydronaphthyl)acetonitrile
Aluminium isopropoxide (2.05 g, 10.0 mmol) is added to a solution of the compound
obtained in Step B (680 mg, 3.15 mmol) in isopropanol (15 mL) at ambient temperature.
The reaction mixture is refluxed. When the reagents have been completely consumed, a
few crystals of p-toluenesulphonic acid monohydrate are added and a Dean-Stark
apparatus is mounted on top of the flask. The mixture is again refluxed for 1 hour, during
which the isopropanol is gradually replaced with toluene by means of the Dean-Stark
apparatus. A 1N HCl solution is then added and the resulting phases are separated. The
aqueous phase is extracted with ethyl acetate, the organic phases being washed with
S-[2-(4-methoxyphenyl)oxoethyl]-O-ethyl dithiocarbonate is obtained according to the protocol
saturated NaHCO solution and with saturated NaCl solution, then dried over MgSO ,
filtered and concentrated under reduced pressure. The residue is purified by column
chromatography (petroleum ether-ethyl acetate: 80-20) to yield the title product in the form
of an oil in a yield of 85%.
HRMS (EI, m/z) Calc. for C H NO : 199.0997; found: 199.1001.
13 13
Step D: (7-Methoxynaphthyl)acetonitrile
Method A:
To a solution of the compound obtained in Step C (1.0 g, 5.0 mmol) in dichloromethane
(50 mL) at ambient temperature there is added DDQ (1.4 g, 6.0 mmol). The reaction
mixture is stirred for 2 days and is then washed with saturated NaHCO solution. The
aqueous phase is extracted with ethyl acetate, the organic phase being washed with
saturated NaCl solution, dried over MgSO , filtered and concentrated under reduced
pressure. The residue is purified by column chromatography (petroleum ether-ethyl
acetate: 80-20) to yield the title product in solid form in a yield of 55%.
Method B:
To a solution of TCQ (615 mg, 2.5 mmol) in toluene (1.5 mL) heated to 80°C there is
added the compound obtained in Step C (462 mg, 2.3 mmol) dissolved in toluene (3.5 mL).
The mixture is then refluxed for 2.5 hours and is then diluted with water and extracted with
petroleum ether. The organic phase is washed with NaOH solution (30% by weight) and
with water and is then dried over MgSO , filtered and concentrated under reduced
pressure. The residue is purified by column chromatography (petroleum ether-ethyl
acetate: 80-20) to yield the title product in solid form in a yield of 61%.
HRMS (EI, m/z) Calc. for C H NO: 197.0841; found: 197.0838.
13 11
Step E: N-[2-(7-Methoxynaphthyl)ethyl]acetamide
The reaction was carried out on a larger batch in order to optimise the yield obtained:
136 g of Raney nickel, 2.06 L of ethanol and 0.23 L of water are introduced into an 8 L
reactor. Whilst stirring at 70°C and under 30 bars of hydrogen, the compound obtained in
described in Batanero, B. et al., J. Org. Chem. 2001, 66, 320.
Step D (0.8 kg) dissolved in acetic anhydride (2.4 L) is slowly added. At the end of the
addition, the reaction mixture is stirred for 1 hour under hydrogen at 30 bar, the reactor is
then decompressed and the liquors are filtered. After concentration of the mixture, the
residue is crystallised from a mixture of ethanol/water 35/65 to yield the title product in a
yield of 89% and with a chemical purity greater than 99%.
Melting point: 108°C
E Ex xa am mp plle e 2 2: : N N- -[ [2 2- -( (7 7- -M Me et th ho ox xy y- -1 1- -n na ap ph ht th hy yll) )e et th hy yll] ]a ac ce et ta am miid de e
Step A: (7-Methoxy-1,2-dihydronaphthyl)acetonitrile
A solution of allyl cyanide (6.75 mL, 84.0 mmol) and S-[2-(4-methoxyphenyl)
oxoethyl]-O-ethyl dithiocarbonate (11.3 g, 42.0 mmol) in ethyl acetate (45 mL) is heated
at reflux for 15 minutes under a nitrogen atmosphere. There is added, firstly, an amount of
dilauroyl peroxide (10 mol%) to the solution under reflux. After 1 hour 30 minutes,
another amount of dilauroyl peroxide (5 mol%) is also introduced. When the reagents have
been completely consumed, the mixture is cooled to ambient temperature and concentrated
under reduced pressure. The crude mixture is redissolved in chlorobenzene (640 mL) and
the solution is refluxed for 15 minutes under a nitrogen atmosphere. Dilauroyl peroxide is
then gradually added to the solution under reflux (10 mol% every 10 minutes). When the
reaction is complete, the mixture is cooled to ambient temperature and concentrated under
reduced pressure. Acetonitrile is then introduced in order to cause a large part of the
dilauroyl peroxide compounds to precipitate out. The mixture is then filtered and
concentrated under reduced pressure. Half the crude oil thereby obtained is redissolved in
isopropanol (100 mL) at ambient temperature in the presence of aluminium isopropoxide
(13.6 g, 66.6 mmol). The reaction mixture is refluxed. When the reagents have been
completely consumed, a few crystals of p-toluenesulphonic acid monohydrate are added
and a Dean-Stark apparatus is mounted on top of the flask. The mixture is again refluxed
for 2 hours, during which the isopropanol is gradually replaced with toluene by means of
the Dean-Stark apparatus. A 1N HCl solution is then added and the resulting phases are
separated. The aqueous phase is extracted with ethyl acetate, the organic phases being
washed with saturated NaHCO solution and with saturated NaCl solution, then dried over
MgSO , filtered and concentrated under reduced pressure. The residue is purified by
column chromatography (petroleum ether-ethyl acetate: 80-20) to yield the title product in
the form of an oil in a yield of 24%.
HRMS (EI, m/z) Calc. for C H NO : 199.0997; found: 199.1001.
13 13
Step B: (7-Methoxynaphthyl)acetonitrile
The procedure is analogous to Step D of Example 1.
Step C: N-[2-(7-Methoxynaphthyl)ethyl]acetamide
The procedure is analogous to Step E of Example 1.
Claims (18)
1. Process for the industrial synthesis of the compound of formula (I): NHCOMe (I), characterised in that allyl cyanide of formula (II): (II) is reacted, in the presence of a free radical initiator, with a compound of formula (III): (III), 5 wherein Xa represents a group -S-C(S)-OR in which R represents a linear or branched (C -C )alkyl group, to yield the compound of formula (IV): (IV), wherein Xa is as defined hereinbefore, it being possible for this latter compound optionally to be isolated, before being 10 subjected to a cyclisation reaction in the presence of a free radical initiator in order to form the compound of formula (V): (V), which compound of formula (V) also optionally may be isolated, which is subjected to a reduction-dehydration reaction to yield the compound of formula (VI): (VI), which is then subjected to an aromatisation reaction to yield the compound of 5 formula (VII): (VII), which is subjected to reduction using hydrogen in the presence of Raney nickel in a polar protic medium and to reaction with acetic anhydride to yield the compound of formula (I), which is isolated in the form of a solid.
2. Process for the synthesis of the compound of formula (I) according to claim 1 10 characterised in that the compound of formula (VII) is then subjected to reduction using hydrogen in the presence of Raney nickel in an ammoniacal ethanol medium and then converted into a salt using hydrochloric acid to yield the compound of formula (VIII): (VIII), which is successively subjected to the action of sodium acetate and then acetic anhydride to yield the compound of formula (I), which is isolated in the form of a solid. 5 3 3..
Process for the synthesis of the compound of formula (I) according to claim 1 characterised in that the compound of formula (VII) is subjected to reduction by hydrogen in the presence of Raney nickel in a medium comprising acetic anhydride in a polar protic medium to yield the compound of formula (I), which is isolated in the form of a solid. 10 4 4..
Process for the synthesis of the compound of formula (I) according to claim 1, characterised in that the group Xa = -S-C(S)-OC H . 5 5..
Process for the synthesis of the compound of formula (I) according to claim 1, characterised in that the free radical reactions are initiated by thermal means at a temperature of from 50 to 140°C. 15 6 6..
Process for the synthesis of the compound of formula (I) according to claim 1, characterised in that cyclisation of the compound of formula (IV) is carried out at a temperature of from 130 to 135°C.
7. Process for the synthesis of the compound of formula (I) according to claim 1, characterised in that the step of addition of the compound of formula (II) to the 20 compound of formula (III) and that of cyclisation of the compound of formula (IV) are initiated in the presence of dilauroyl peroxide.
8 8.. Process for the synthesis of the compound of formula (I) according to claim 1, characterised in that the step of addition of the compound of formula (II) to the compound of formula (III) is carried out in chlorobenzene.
9. Process for the synthesis of the compound of formula (I) according to claim 1, 5 characterised in that the step of cyclisation of the adduct of formula (IV) to form the compound of formula (V) is carried out in ethyl acetate.
10. Synthesis process according to claim 1, characterised in that conversion of the compound of formula (V) into the compound of formula (VI) is carried out in the presence of aluminium isopropoxide. 10 11.
Synthesis process according to claim 1, characterised in that conversion of the compound of formula (V) into the compound of formula (VI) is carried out in isopropanol. 1 12 2..
Synthesis process according to claim 1, characterised in that a catalytic amount of p-toluenesulphonic acid is added to the mixture at the end of conversion of the 15 compound of formula (V) into the compound of formula (VI). 1 13 3..
Synthesis process according to claim 1, characterised in that aromatisation of the compound of formula (VI) is carried out in the presence of a quinone. 1 14 4..
Synthesis process according to claim 1, characterised in that aromatisation of the compound of formula (VI) is carried out in the presence of tetrachlorobenzoquinone at 20 the reflux of toluene. 1 15 5..
Compound of formula (V) as defined in claim 1 for use as an intermediate in the synthesis of agomelatine. 1 16 6..
Use of the compound of formula (V) as defined in claim 15 in the synthesis of agomelatine.
17. Compound of formula (VI) as defined in claim 1 for use as an intermediate in the synthesis of agomelatine.
18. Use of the compound of formula (VI) as defined in claim 17 in the synthesis of agomelatine. 5 1 19 9.. A compound of formula I when prepared according to the process of claim 1, substantially as herein described with reference to any example thereof. 2 20 0.. A process according to claim 1, substantially as herein described with reference to any example thereof. 2 21 1.. A compound according to claim 15 or claim 17, substantially as herein described with 10 reference to any example thereof. 2 22 2.. A use according to claim 16 or claim 18, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1100024A FR2970000B1 (en) | 2011-01-05 | 2011-01-05 | NEW PROCESS FOR THE SYNTHESIS OF AGOMELATIN |
FR11.00024 | 2011-01-05 | ||
PCT/FR2012/000005 WO2012113999A1 (en) | 2011-01-05 | 2012-01-04 | Process and intermediates for synthesizing agomelatine |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ612173A NZ612173A (en) | 2015-08-28 |
NZ612173B2 true NZ612173B2 (en) | 2015-12-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101135336B1 (en) | New process for the synthesis of agomelatine | |
AU2012220474B2 (en) | Process and intermediates for synthesizing agomelatine | |
EP2134673A1 (en) | Improved process for preparing o-chloromethylphenylglyoxylic esters, improved process for preparing (e)-2-(2-chloromethylphenyl)-2-alkoximinoacetic esters, and novel intermediates for their preparation | |
JP5667186B2 (en) | Process for the preparation of pyrazolecarboxylic amides | |
NZ612173B2 (en) | Process and intermediates for synthesizing agomelatine | |
AU2012204817B2 (en) | Novel process for synthesizing agomelatine | |
NZ612163B2 (en) | New process for the synthesis of agomelatine | |
OA16477A (en) | New process for the synthesis of agomelatine. | |
CN113511979A (en) | Synthesis method and application of propranolol |